L Ruiz

Summary

Affiliation: Hospital Universitari Germans Trias i Pujol
Country: Spain

Publications

  1. ncbi request reprint HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
    L Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 15:F19-27. 2001
  2. ncbi request reprint Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load
    A Arno
    Retrovirology Laboratory irsiCaixa Foundation, Immunology Department, HIV Unit, University Hospital Germans Trias i Pujol, Barcelona, Spain
    J Infect Dis 180:56-60. 1999
  3. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
  4. ncbi request reprint Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
    L Ruiz
    IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 27:229-36. 2001
  5. ncbi request reprint Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
  6. ncbi request reprint High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
  7. ncbi request reprint Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    A Tuldrá
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
    J Acquir Immune Defic Syndr 25:221-8. 2000
  8. ncbi request reprint Short-term anti-HIV activity of the combination of didanosine and hydroxyurea
    B Clotet
    Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 1:189-93. 1996
  9. ncbi request reprint Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia
    M A Martinez
    Laboratori de Retrovirologia, Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Spain
    Virology 256:180-7. 1999
  10. doi request reprint Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz
    J M Llibre
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    J Antimicrob Chemother 62:909-13. 2008

Collaborators

Detail Information

Publications63

  1. ncbi request reprint HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
    L Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 15:F19-27. 2001
    ..To evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection...
  2. ncbi request reprint Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load
    A Arno
    Retrovirology Laboratory irsiCaixa Foundation, Immunology Department, HIV Unit, University Hospital Germans Trias i Pujol, Barcelona, Spain
    J Infect Dis 180:56-60. 1999
    ..05). Subcutaneous rIL-2 once a day in combination with HAART was well tolerated and improved immunologic surface markers in patients with advanced HIV infection...
  3. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  4. ncbi request reprint Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
    L Ruiz
    IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 27:229-36. 2001
    ..Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy...
  5. ncbi request reprint Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
    ..Maintenance of viral suppression was equivalent in both treatment groups. Additional data with longer follow-up are needed to confirm these results...
  6. ncbi request reprint High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
    ..This therapeutic efficacy is strongly implemented by a switch at the lower HIV-1 RNA levels...
  7. ncbi request reprint Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    A Tuldrá
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
    J Acquir Immune Defic Syndr 25:221-8. 2000
    ..Interventions to ensure a high level of adherence during a relatively long-term period of therapy are necessary...
  8. ncbi request reprint Short-term anti-HIV activity of the combination of didanosine and hydroxyurea
    B Clotet
    Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 1:189-93. 1996
    ..In conclusion, hydroxyurea in combination with didanosine was well tolerated and led to a reduction in viral load mainly in patients who were initially naive to didanosine...
  9. ncbi request reprint Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia
    M A Martinez
    Laboratori de Retrovirologia, Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Spain
    Virology 256:180-7. 1999
    ..Finally, the genetic analysis of the env gene shows a reduction in PBMC env viral population diversity after long-term response to the therapy in all the patients analyzed...
  10. doi request reprint Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz
    J M Llibre
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    J Antimicrob Chemother 62:909-13. 2008
    ..To evaluate the expected activity of etravirine in clinical samples, according to mutational patterns associated with decreased virological response (VR)...
  11. pmc Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood
    M Bofill
    Institucio Catalana de Recerca i Estudis Avancats, Badalona, Spain
    Clin Exp Immunol 138:460-5. 2004
    ....
  12. pmc Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10
    G Coma
    Fundacio irsiCaixa, Badalona, Spain
    Clin Exp Immunol 145:535-44. 2006
    ..In particular, those that may regulate angiogenesis and promote the recruitment of monocytes, activated T cells (CXCL9 and CXCL10) and granulocytes (CXCL8)...
  13. ncbi request reprint Longitudinal study on mitochondrial effects of didanosine-tenofovir combination
    Sonia Lopez
    Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 22:33-9. 2006
    ..The particular relevance of either ddI, TDF, or any interaction between them in such a mitochondrial dysfunction remains to be established...
  14. ncbi request reprint Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS 20:2075-80. 2006
    ..To analyse the genetic changes in the gp41 protein in HIV-infected patients with detectable plasma viraemia receiving a long-term salvage enfuvirtide regimen...
  15. ncbi request reprint Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance
    Margarita Bofill
    Institució Catalana de Recerca i Estudis Avangats, HIV Unit, Hospital Universitari Germans Trias i Pujol, Ctra Canyet s n 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 22:893-6. 2006
    ..However, the probability of restarting therapy in these two groups of patients was independent of the levels of naive T cells, RTEs, or TRECs...
  16. ncbi request reprint Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide
    Anna Bonjoch
    Lluita contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Auntònoma de Barcelona, Badalona, Spain
    AIDS 20:1896-8. 2006
    ..5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available...
  17. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006
    ..Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4...
  18. ncbi request reprint Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients
    Monica Guma
    Molecular Immunopathology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    J Infect Dis 194:38-41. 2006
    ..These results support the conclusion that changes in the NKR repertoire in HIV1-positive patients are related to a concomitant HCMV infection...
  19. ncbi request reprint The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
    David A van de Vijver
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04 614, 3584 CX Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 41:352-60. 2006
    ..This study compared the genetic barrier between subtypes using some 2000 HIV-1 sequences (>600 of non-B subtype) isolated from anti-retroviral-naive patients in Europe...
  20. pmc Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus
    Rika Draenert
    Howard Hughes Medical Institute, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    J Exp Med 203:529-39. 2006
    ..These results reveal considerable concordance of adaptive cellular and humoral immune responses and HIV evolution in the same genetic environment, suggesting constraints on mutational pathways to HIV immune escape...
  21. ncbi request reprint Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 11:47-51. 2006
    ..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients...
  22. ncbi request reprint Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    Lidia Ruiz
    Fundació IrsiCaixa and HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 21:169-78. 2007
    ..We evaluated the safety of CD4 cell count and plasma HIV-1 RNA (pVL)-guided treatment interruptions (GTI) and determined predictors of duration of treatment interruption...
  23. ncbi request reprint Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients
    Guillermo Robert de Arquer
    Fundacio irsiCaixa, HIVACAT, Hospital Universitari Germans Trias i Pujol, Ctra Canyet sn, 08916 Badalona, Spain
    J Leukoc Biol 82:72-8. 2007
    ..Furthermore, the percentage of IL-12Rbeta1-positive cells correlated inversely with the CD4 nadir of patients, suggesting that deregulation of the IL-12 and IL-18 pathways may play a role in the immunopathogenesis of HIV-1 infection...
  24. ncbi request reprint HIV-1 subtypes and response to combination antiretroviral therapy in Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 11:707-15. 2006
    ..Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide...
  25. doi request reprint Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  26. doi request reprint Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions
    Laila Darwich
    IrsiCaixa Foundation, Center for Epidemiological Studies on Sexually Transmitted Infections and AIDS in Catalonia, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:725-32. 2008
    ..A genotypic profile could provide clinicians with a predictive tool for time off therapy when TI is required in patients with suppressed viremia in whom nadir CD4(+) count is not available...
  27. doi request reprint Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  28. ncbi request reprint Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:400-4. 2008
    ..Cellular cholesterol is essential for HIV replication and may control HIV spread. HIV, in turn, appears to control cholesterol metabolism...
  29. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  30. ncbi request reprint Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
    ..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated...
  31. ncbi request reprint Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments
    César Garriga
    Centro de Biologia Molecular Severo Ochoa, CSIC Universidad Autonoma de Madrid, Cantoblanco, Madrid, Spain
    J Med Virol 79:1617-28. 2007
    ....
  32. ncbi request reprint Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease
    Concepcion Casado
    Centro Nacional de Microbiologia Instituto de Salud Carlos III, Madrid, Spain
    J Infect Dis 196:895-9. 2007
    ..Dual infections occur in patients with long-term, nonprogressive disease, with no immediate clinical manifestations. Such occurrences could indicate a general phenomenon in natural HIV-1 infections...
  33. ncbi request reprint The development of artificial neural networks to predict virological response to combination HIV therapy
    Brendan Larder
    The HIV Resistance Response Database Initiative, London, UK
    Antivir Ther 12:15-24. 2007
    ..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge...
  34. ncbi request reprint Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    AIDS 21:721-32. 2007
    ..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting...
  35. ncbi request reprint Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    Antivir Ther 10:791-802. 2005
    ....
  36. ncbi request reprint Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
    Annemarie M J Wensing
    Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
    J Infect Dis 192:958-66. 2005
    ..Widespread transmission of drug-resistant variants has the disturbing potential of limiting future therapy options and affecting the efficacy of postexposure prophylaxis...
  37. ncbi request reprint HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure
    Julia G Prado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Clin Infect Dis 41:729-37. 2005
    ....
  38. ncbi request reprint Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  39. ncbi request reprint A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy
    Jan Weber
    Department of Virology, Lerner Research Institute, Cleveland Clinic Foundation, NN10, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Gen Virol 84:2217-28. 2003
    ..However, this new assay, based on HIV-1 isolates, may be useful to quantify replicative fitness in viruses from patients treated simultaneously with antiretroviral drugs targeting different genomic regions of HIV-1 (e.g. pol and env)...
  40. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial
    Javier Martinez-Picado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
    Ann Intern Med 139:81-9. 2003
    ..Mathematical modeling has suggested that alternating antiretroviral regimens while patients' viral load remains suppressed would minimize HIV resistance mutations...
  41. pmc Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals
    Javier Martinez-Picado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Virol 76:12344-8. 2002
    ..Analyses of length variation and of clonal sequences demonstrated highly unpredictable evolution, which may limit the strengthening of HIV-specific immune responses by STIs because of the variability in exposure to viral antigens...
  42. ncbi request reprint Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts
    Bonaventura Clotet
    Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
    HIV Clin Trials 3:316-23. 2002
    ..Although L90M has been observed rarely to date under nelfinavir selection, data on the relative incidence of these two mutations on failure of first-line nelfinavir HAART are sparse...
  43. ncbi request reprint Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:1383-9. 2002
    ..Treatment simplification approaches in which PI are replaced by nevirapine (NVP) have been shown to improve PI-related toxicity...
  44. ncbi request reprint Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
    Julia G Prado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Spain
    AIDS 16:1009-17. 2002
    ..To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selected mutations...
  45. ncbi request reprint Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions
    Javier Martinez-Picado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:895-9. 2002
    ..The potential for selection of drug-resistant quasi-species remains a major concern of such a treatment strategy...
  46. ncbi request reprint Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Jacques Fellay
    Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 359:30-6. 2002
    ..This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes...
  47. ncbi request reprint Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
    Cristina Tural
    HIV Clinical Unit and IrsiCaixa Retrovirology Laboratory, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:209-18. 2002
    ..To determine whether HIV-1 genotyping and expert advice add additional short-term virologic benefit in guiding antiretroviral changes in HIV+ drug-experienced patients...
  48. ncbi request reprint Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression
    Eugenia Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Clin Infect Dis 34:504-10. 2002
    ..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective...
  49. pmc Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection
    Simon D W Frost
    Department of Pathology, University of California, San Diego, California 92103, USA
    J Virol 76:968-79. 2002
    ....
  50. pmc Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection
    Rika Draenert
    Howard Hughes Medical Institute, Charlestown, MA 02129, USA
    J Exp Med 199:905-15. 2004
    ..These results demonstrate that allele-associated sequence variation within the flanking region of CTL epitopes can alter antigen processing. Identifying such mutations is of major relevance in the construction of vaccine sequences...
  51. pmc Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1
    Javier Martinez-Picado
    IrsiCaixa Foundation Hospital Germans Trias i Pujol, Ctra de Canyet, s n 08916 Badalona, Spain
    J Virol 79:5907-13. 2005
    ..The potential clinical relevance of protease inhibitor hypersusceptibility and low replication capacity to virologic response to protease inhibitor-based therapies deserves to be investigated further...
  52. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Antivir Ther 9:889-93. 2004
    ..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term...
  53. ncbi request reprint Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
    ..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision...
  54. pmc Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification
    Javier Martinez-Picado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Clin Microbiol 43:436-8. 2005
    ..This observation might help to explain some unexpected HIV-1 genotypes...
  55. ncbi request reprint Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Germans Trias i Pujol Hospital, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:47-52. 2005
    ..To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression...
  56. ncbi request reprint Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
    Antivir Ther 9:787-800. 2004
    ....
  57. pmc Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
    Esteban Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
    Antimicrob Agents Chemother 48:4256-62. 2004
    ....
  58. ncbi request reprint Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215
    Julia G Prado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Virology 326:103-12. 2004
    ..Therefore, the RT residue 215 plays a critical role in both replication capacity and drug resistance of multidrug-resistant viruses containing the i69SS...
  59. ncbi request reprint Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
    ..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression...
  60. ncbi request reprint Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load
    Eugenia Negredo
    Lluita contra la SIDA and Irsicaixa Foundations Germans Trias i Pujol Hospital, Badalona, Spain
    AIDS 18:459-63. 2004
    ..We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression...
  61. pmc Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions
    Julia G Prado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Clin Microbiol 42:1620-5. 2004
    ....
  62. pmc Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission
    Nuria Izquierdo-Useros
    IrsiCaixa Foundation, Badalona, Spain
    J Virol 81:7559-70. 2007
    ....
  63. pmc Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region
    Cristina Villena
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Ctra de Canyet s n, 08916 Badalona, Spain
    J Virol 81:4713-21. 2007
    ..These effects correlated with impaired Gag cleavage and could be attributed to delayed maturation and decreased production of active protease in those variants...